EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Starpharma Holdings's enterprise value is $12.45 Mil.
Starpharma Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $1.92 Mil. Therefore, Starpharma Holdings's EV-to-Revenue for today is 6.48.
The historical rank and industry rank for Starpharma Holdings's EV-to-Revenue or its related term are showing as below:
SPHRF'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.98 Med: 96.27 Max: 735.29
Current: 6.52
During the past 13 years, the highest EV-to-Revenue of Starpharma Holdings was 735.29. The lowest was 1.98. And the median was 96.27.
SPHRF's EV-to-Revenue is ranked better than 52.26% of 997
companies
in the Biotechnology industry
Industry Median: 7.28
vs SPHRF: 6.52
The historical data trend for Starpharma Holdings's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Starpharma Holdings's EV-to-Revenue
For the Biotechnology subindustry, Starpharma Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starpharma Holdings's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Starpharma Holdings's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Starpharma Holdings's EV-to-Revenue falls into.
Starpharma Holdings's current Enterprise Value is $12.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Starpharma Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $1.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Starpharma Holdings's share price for today is $0.0597.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Starpharma Holdings EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Starpharma Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SPHRF has been successfully added to your 